March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Effect Of Topical IL-1RA On Signs And Symptoms Of Dry Eye Disease In Patients With Ocular Graft-versus-host Disease (GVHD)
Author Affiliations & Notes
  • Hasanain Shikari
    Cornea, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Francisco Amparo
    Cornea, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Mohammad Dastjerdi
    Cornea, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Andre Okanobo
    Cornea, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Giulio Ferrari
    Cornea, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Reza Dana
    Cornea, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Hasanain Shikari, None; Francisco Amparo, None; Mohammad Dastjerdi, None; Andre Okanobo, None; Giulio Ferrari, None; Reza Dana, None
  • Footnotes
    Support  NIH-EY019098
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 579. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hasanain Shikari, Francisco Amparo, Mohammad Dastjerdi, Andre Okanobo, Giulio Ferrari, Reza Dana; Effect Of Topical IL-1RA On Signs And Symptoms Of Dry Eye Disease In Patients With Ocular Graft-versus-host Disease (GVHD). Invest. Ophthalmol. Vis. Sci. 2012;53(14):579.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effect of off-label use of topical interleukin-1 receptor antagonist (IL-1Ra) on symptoms and corneal flourescein staining in patients with dry eye disease due to ocular GVHD.

Methods: : Retrospective review of 74 eyes (37 subjects) treated with off-label topical IL-1Ra drops three times a day for 12 weeks was performed. Symptoms were evaluated using the Ocular Surface Disease Index (OSDI) questionnaire. Corneal Flourescein Staining (CFS) was evaluated using the modified Oxford grading system. Symptom scores and average CFS of both eyes were compared to baseline values.

Results: : At baseline mean OSDI score was 48±23 and mean CFS score was 2.1±1. Patients show statistically significant change beginning at 6 weeks for OSDI (p=0.001) and 2 weeks for CFS (p<0.05). After completing 12 weeks of treatment, patients showed a statistically significant improvement in OSDI (40±26, p=0.01) and CFS (1.4±0.8, p<0.001) compared to baseline values. Interestingly, the group of patients with severe symptoms at baseline (OSDI>33) achieved a mean reduction of 18±23 (p<0.001) in OSDI score at week 12.

Conclusions: : Treatment with topical IL-1Ra significantly reduces symptoms (OSDI) and corneal flourescein staining in patients with ocular GVHD and dry eye disease.

Keywords: cornea: tears/tear film/dry eye • clinical (human) or epidemiologic studies: outcomes/complications • cytokines/chemokines 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×